A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

ClinicalTrials.gov ID: NCT05678257

Public ClinicalTrials.gov record NCT05678257. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 24, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unresectable Metastatic Colorectal Cancer

Study identification

NCT ID: NCT05678257
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: NuCana plc; Other
Enrollment: 180 participants

Conditions and interventions

Conditions

Interventions

Fosifloxuridine Nafalbenamide Drug
Leucovorin Drug
Irinotecan Drug
Bevacizumab Biological
5-FU Drug

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 17, 2023
Primary completion: Aug 28, 2024
Completion: Aug 28, 2024
Last update posted: Sep 11, 2025

2023 – 2024

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 15

Facility	City	State	ZIP	Site status
Helen F. Graham Cancer Center	Newark	Delaware	19713	—
Georgetown University Medical Center	Washington D.C.	District of Columbia	20007	—
University of Florida Health Medical Oncology - Davis Cancer Pavilion	Gainesville	Florida	32610	—
University of Iowa Hospitals and Clinics	Iowa City	Iowa	52242	—
Cancer Center of Kansas	Wichita	Kansas	67214	—
Norton Cancer Institute	Louisville	Kentucky	40202	—
Boston Medical Center	Boston	Massachusetts	02118	—
University of Massachusetts Worcester	Worcester	Massachusetts	01655	—
Barbara Ann Karmanos Cancer Institute	Detroit	Michigan	48201	—
Morristown Medical Center	Morristown	New Jersey	07960	—
The Christ Hospital Cancer Center	Cincinnati	Ohio	45219	—
Texas Oncology - Baylor Charles A. Sammons Cancer Center	Dallas	Texas	75246	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—
USOR - Texas Oncology Northeast Texas	Tyler	Texas	75702	—
Fred Hutchinson Cancer Center at Evergreen Health	Kirkland	Washington	98034	—
Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center	Vancouver	Washington	98684	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05678257, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 11, 2025 · Synced Jul 24, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05678257 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →